Loading…
FibroBiologics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in FBLG.
▼ -99.8% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $4.50 | $40.00 | |
| P/B | — | 2.4x | 25.7x |
| EPS | -$8.40 | -$6.80 | |
| ROE | — | -302.89% | -408.08% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| APUSApimeds Pharmaceuticals US, Inc. | $6.39 | — | 9.8x | — | — | $9.64M |
| AMSAmerican Shared Hospital Services | $1.47 | — | 0.4x | — | -12.06% | $9.78M |
| XBIOXenetic Biosciences, Inc. | $3.98 | — | 1.2x | — | -47.04% | $9.33M |
| IMRNImmuron Ltd | $1.15 |
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Company description provided by Yahoo Finance.
| — |
| 1.0x |
| — |
| -39.68% |
| $9.28M |
| SINTSintx Technologies, Inc. | $1.50 | — | 2.1x | — | -255.86% | $10M |
| BFRGBullFrog AI Holdings, Inc. | $0.54 | — | 1.4x | — | -130.71% | $10.01M |